Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL19260557

CNc1c2ccccc2nc2cc(OCCCN(C)C)c(OC)cc12.O=C(O)C(F)(F)F

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 4/20 0.44
▸ EHMT2 Q96KQ7 3/20 0.44
▸ KDM1A O60341 1/20 0.44
▸ RCOR1 Q9UKL0 1/20 0.44
▸ RET P07949 1/20 0.43
▸ KIF5B P33176 1/20 0.43
▸ AXL P30530 1/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ BCHE P06276 1/20 0.42
▸ ACHE P22303 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ SLC2A1 P11166 1/20 0.42
▸ APOBEC3A P31941 1/20 0.42
▸ RAD52 P43351 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ APOBEC3G Q9HC16 1/20 0.42
▸ KDM4E B2RXH2 2/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19260524 0.91 EGFR (0.50) EGFREHMT2KDM1ARCOR1RET
Trifluoroacetic Acid SCHEMBL19260559 0.91 KDM4E (0.45) EGFREHMT2BCHEACHEPOLB
Trifluoroacetic Acid SCHEMBL20720787 0.87 EGFR (0.44) EGFREHMT2KDM1ARCOR1RET
SCHEMBL20720752 0.81 CACNA2D1 (0.50) EGFREHMT2POLBKMT2AKDM4E
SCHEMBL20720782 0.80 ACHE (0.42) EGFRAXLRAB9ABCHEACHE
Trifluoroacetic Acid SCHEMBL20720749 0.78 KIT (0.47) EGFREHMT2RETKIF5B
Trifluoroacetic Acid SCHEMBL19260723 0.78 EGFR (0.46) EGFRBCHEACHEPOLBKMT2A
SCHEMBL19260709 0.77 EGFR (0.49) EGFREHMT2KDM1ARCOR1KDM4E
Trifluoroacetic Acid SCHEMBL20720740 0.77 KIT (0.49) EGFREHMT2
SCHEMBL17423250 0.76 RAD52 (0.74) EHMT2KDM1ARCOR1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11254651-B2 Histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2022-02-22 — — US disclosed
EP-3416963-B1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2021-07-28 — — EP disclosed
US-20190047981-A1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2019-02-14 — — US disclosed
EP-3416963-A1 HISTONE METHYLTRANSFERASE INHIBITORS Global Blood Therapeutics, Inc. (US) 2018-12-26 — — EP disclosed
WO-2017142947-A1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2017-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190047981-A1 HISTONE METHYLTRANSFERASE INHIBITORS EHMT1, EHMT2, BMI1 EGFR 4848/4885EHMT2 2/4885KDM1A 15/4885
US-11254651-B2 Histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 EGFR 4848/4885EHMT2 2/4885KDM1A 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback